Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million
04/08/2026 21:02
BRIEF-Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million Aug 04 (Reuters) - Syndax Pharmaceuticals Q2 operating expenses USD 112.783 million.
- Q2 net income USD -49.363 million vs. IBES estimate USD -39.4 million
- Q2 cash & investments USD 575.1 million
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million